Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256178 | 0.80 | MAPT (0.70) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL968875 | 0.79 | PIK3CD (0.57) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4859450 | 0.79 | MAP4K4 (0.56) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15614090 | 0.78 | MAP4K4 (0.59) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL12193535 | 0.76 | MAPT (0.52) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2021249 | 0.76 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL27643315 | 0.76 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1951940 | 0.76 | MAPT (0.52) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL9613271 | 0.76 | LMNA (0.52) | NPC1RAB9ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5321375 | 0.76 | MAP4K4 (0.67) | NPC1RAB9ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE HOLDINGS CORPORATION | 2020-10-08 | — | — | US | disclosed |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3443958-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2018-10-04 | — | — | US | disclosed |
| EP-3034075-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9944645-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | NPC1 3650/4885RAB9A 3414/4885SMN1; SMN2 3371/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | NPC1 2655/4885RAB9A 319/4885SMN1; SMN2 3842/4885 |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | NPC1 3792/4885RAB9A 2986/4885SMN1; SMN2 2945/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | NPC1 3650/4885RAB9A 3414/4885SMN1; SMN2 3371/4885 |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | NPC1 3792/4885RAB9A 2986/4885SMN1; SMN2 2945/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | NPC1 2655/4885RAB9A 319/4885SMN1; SMN2 3842/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | NPC1 3650/4885RAB9A 3414/4885SMN1; SMN2 3371/4885 |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | NPC1 3792/4885RAB9A 2986/4885SMN1; SMN2 2945/4885 |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | NPC1 3792/4885RAB9A 2986/4885SMN1; SMN2 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.